Massachusetts-based brain implant company Axoft raised a $55M Series A and says it tested its device in a Shanghai patient, with plans for more trials in China (Bloomberg)

Axoft, a Massachusetts-based brain implant company, secured $55M in Series A funding and has begun clinical testing in China, signaling accelerating competition in the neurotechnology space and the strategic importance of international markets for medical device innovation. For IT organizations, this highlights the growing convergence of biotech and computing infrastructure, particularly as companies expand into regulated markets with complex data sovereignty and compliance requirements. The geopolitical dimension—with trials occurring in Shanghai—underscores that technology leaders must prepare for distributed clinical operations, cross-border data management, and evolving regulatory frameworks around medical AI and neural interfaces.